Category Archives: Stem Cell Research

Stem cells possess the unique ability to differentiate into many distinct cell types in the body, including brain cells, but they also retain the ability to produce more stem cells, a process termed self-renewal. There are multiple types of stem cell, such as embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, and adult or somatic stem cells. While various types of stem cells share similar properties there are differences as well. For example, ES cells and iPS cells are able to differentiate into any type of cell, whereas adult stem cells are more restricted in their potential. The promise of all stem cells for use in future therapies is exciting, but significant technical hurdles remain that will only be overcome through years of intensive research.

NINDS supports a diverse array of research on stem cells, from studies of the basic biology of stem cells in the developing and adult mammalian brain, to studies focusing on nervous system disorders such as ALS or spinal cord injury. Other examples of NINDS funded research include using iPS cells to derive dopamine-producing neurons that might alleviate symptoms in patients with Parkinsons disease, and using ES cells to generate cerebral organoids to model Zika virus infection.

More here:
Focus On Stem Cell Research | National Institute of ...

Ted Dawson, M.D., Ph.D., professor of neurology and co-director of NeuroICE explains where we are in using stem cells to treat Parkinsons Disease.

Were creating induced pluripotent stem (iPS) cells from patients with Parkinsons disease with the intent of turning them into dopamine neurons that we can study in a dish and also put into animals. We want to see if human iPS derived neurons grown in culture or in a mouse can lead to disease, and if it can, to study the mechanisms of why cells degenerate and test our hypotheses, drugs and targets in human cells.

If you look at the work thats been done in neurodegenerative diseases in animal models, weve been good at slowing progression of disease, but when we go to humans, the trials fail. So why is that? Perhaps because in mice were able to intervene very early in the disease, but in humans were treating late. Maybe the treatment would work if we treated early in humans, but this would require the ability to diagnosis the disease prior to the onset of symptoms. The other possibility is that Parkinsons disease in a mouse is different than a man.

Using iPS cells we can test new therapies in human neurons for the first time. One of the reasons there have been tremendous new therapies with cancers is that scientists can biopsy human tumors and use those cells to design drugs. Now stem cells are putting us in a position to be able to study neurodegenerative diseases in a similar way.

For developmental diseases such as Down syndrome and schizophrenia, theres no question in my mind that iPS will change the ways those diseases are studied and treated. With an adult-onset neurodegenerative disorder that takes 50 years to develop in humans, the big question is whether an iPS cell will have Parkinsons disease after growing in a mouse for a few months. We just dont know. But we need to do the experiment.

Lots of people thought Parkinsons was going to be low hanging fruit for stem cell transplantation. But we still dont fully understand the transplantation process and how to optimize it. There needs to be a lot of work done to get to that point. And medical therapy for Parkinsons is so advanced that transplantation right now probably isnt going to be any better than what we can already do. But that doesnt mean we shouldnt be forging ahead, using stem cells to discover more about the disease in order to find new drugs as well as refine our ideas about transplantation.

--Interviewed by Maryalice Yakutchik

See the original post here:
Stem Cell Research at Johns Hopkins Medicine: Parkinsons Disease

Andrew Brookes | Getty Images

A representative from CNN reached out to us recently with some questions about stem cells as a potential treatment for so-called long Covid. As they were working on their story, they learned about an interventional clinical trial BioXcellerator has designed to study stem-cell therapy as a possible treatment for Covid-19.

Yes, we are conducting a studyon the use of stem cells to treat cases of acute respiratory distress syndrome (ARDS) that can develop in many Covid-19 patients and cause even higher mortality rates.

But this was a study we designed back in January of 2020. Thats when the global pandemic was in its infancy. The medical community was squarely focused on coping with acute disease, not chronic symptoms that might linger long after a patient recovers. The word Covid was still unfamiliar to many people, and the term long Covid wasn't used until months later.

As we explained to CNN, theres a big difference between acute cases of a disease and chronic conditions that may require different treatment approaches. So such a study would need to be a different one with its own set of research criteria. We pointed out that few, if any, such studies have begun by any research organization, but that didnt reflect a lack of interest.

In fact, quite the contrary. Our medical team is hard at work evaluating just such a study because we need more research to determine whether stem-cell therapy may indeed be a safe and effective treatment for the long-term lingering impact of this disease.

Related:High-Potency 'GoldenCells' Offer Hope to Those With Severe Chronic Back and Neck Pain

In the scientific community, clinical trials are designed to test the safety and efficacy of various treatments using strict controls to measure results. Im proud of our companys participation with leading scientists in a wide variety of studies.

To design these studies, scientists will often publish reviews of prior research to help guide the development of future research. I also take great pride in our participation in these types of reviews. Back in February, BioXcellerator Chief Medical Officer Dr. Karolynn Halpert and our epidemiologist Dr. Santiago Saldarriaga were coauthors of a review on this topic published in the Journal of Stem Cells Research Development & Therapy.

That review, Regenerative Rehabilitation for COVID 19 Sequelae, discusses thevarious disease processes that can impair lung function, prior research on regenerative rehabilitative approaches to treating patients and the potential for stem cells to improve treatment outcomes.

One major theme of this review is how controlling inflammation that results from an overactive immune response might help more patients recover lung function and promote healing of damaged tissue caused by the Covid virus.

Related:This Is HowStem-CellTherapy Treats Serious Brain Injuries

The study we are currently working on is based on treating acute Covid-19 using a specific type of stem cell:mesenchymal stem cells (MSCs) from the Whartons Jelly in donated umbilical cords. Many years of research haveshown the potential of this type of stem cell for reducing harmful inflammation. Earlier research demonstrates how stem cells can modulate the bodys immune response, which may help prevent the production of excess cytokines that can trigger serious inflammation and ARDS. As that journal review explains, MSCs release anti-inflammatory signals and growth factors that may help prevent cell death by reducing that serious inflammation.

And other studies not of stem cells show that reducing systemic inflammation through other treatments may reduce plasma levels of these harmful cytokines and, in turn, may prevent the onset of ARDS or help more patients recover from it.

Whats more, weve developed proprietary protocols for enhancing the potency of the stem cells we use for treatment through a process that include screening stem cells from donated umbilical cords for specific biomarkers that indicate the highest possible potency, selecting only those cells that meet strict criteria for potency and quality, and refining and purifying these cells before reproducing them into infusions of millions of high-potency stem cells for treatment.

This approach has led to treatments for a wide range of diseases and disorders where reducing inflammation and modulating the bodys immune response can be effective at promoting healing.

So back to the question CNN asked. Can stem cells be effective at treating long Covid? Obviously, it will take far more research by many organizations to reach any definitive conclusion, but the question itself demonstrates the importance of understanding that while there are differences between acute disease and chronic conditions, in some cases, results from one study can influence the direction of later studies.

Its also a reflection of how the value of all of our research may be uncertain now, but often becomes clear in the future. Indeed, as Soren Kierkegaard once pointed out, life must be lived looking forward, but it can only be understood by looking back.

Im not sure exactly what well understand when we look back at this unprecedented global pandemic, but we know far more about the role of regenerative medicine and stem-cell therapy in treating a wide range of diseases and how all of usentrepreneurs, scientists and physicians can work together to make even more discoveries to improve the quality of our lives.

Related:The Future of Health: Why Age 100 Will Soon Become 'the New 60'

See original here:
Researching the Safety and Effectiveness of Stem Cells to ...

Line graph. 64% of Americans think it is morally acceptable to conduct stem cell research, while 34% believe it is not.

Next, I'm going to read you a list of issues. Regardless of whether or not you think it should be legal, for each one, please tell me whether you personally believe that in general it is morally acceptable or morally wrong. How about medical research using stem cells obtained from human embryos?

As you may know, the federal government currently provides very limited funding for medical research that uses stem cells obtained from human embryos. Which would you prefer the government to do -- [ROTATED: place no restrictions on government funding of stem cell research, ease the current restrictions to allow more stem cell research, keep the current restrictions in place (or should the government) not fund stem cell research at all]?

Do you think the federal government should -- or should not -- fund research that would use newly created stem cells obtained from human embryos?

How closely have you followed the debate about government funding of stem cell research -- very closely, somewhat closely, not too closely or not closely at all?

As you may know, President Bush gave a speech on stem cell research, and he announced that he WOULD allow the government to fund research using stem cells that have been created in the past in a process that destroyed human embryos. The government WILL NOT fund stem cell research that would destroy additional embryos in the future. Overall, do you approve or disapprove of Bush's decision on stem cell research?

How important is the issue of stem cell research to you -- very important, somewhat important, not too important or not at all important?

Thinking about embryos that have been created in a laboratory by fertilizing a woman's egg outside the womb and have not been implanted in a woman's womb. Which comes closer to your view about this type of embryo -- [ROTATED: the embryo is a human life that should be given the same protection as all other human lives, (or) the embryo has the potential for life, but is not the same as a life, because it cannot develop on its own]?

As you may know, fertility clinics increase a woman's chance to have a child by fertilizing several embryos, but only a few are implanted in her womb to enable her to have a baby. Some stem cells are developed from the remaining embryos that the fertility clinics usually discard. Do you think the federal government should or should not fund research on stem cells from this kind of embryo?

Some stem cells are developed from embryos that are created in laboratories specifically for the purpose of conducting this research and not to help women have a child. Do you think the federal government should or should not fund research on stem cells from this kind of embryo?

Some stem cells may be developed from embryos produced by cloning cells from a living human being rather than by fertilizing a woman's egg. Do you think the federal government should or should not fund research on stem cells from this kind of embryo?

There is another kind of research using stem cells that come just from adults and do not come from embryos at all. The research results in no injury to the person from whom the stem cells are taken. Do you think the federal government should or should not fund research on this kind of stem cells?

For each of the following, please tell me if it is -- very important, somewhat important, not too important, or not at all important -- to you personally. How about -- Medical researchers finding cures for diseases such as Alzheimer's, diabetes, heart disease and spinal cord injury?

For each of the following, please tell me if it is -- very important, somewhat important, not too important, or not at all important -- to you personally. How about -- Preventing human embryos from being used in medical research?

One of the issues involved in this type of research is whether or not the embryos used were developed specifically for stem cell research. Do you think the federal government should or should not allow scientists to fertilize human eggs specifically for the purpose of creating new stem cells?

At least one other country currently allows scientists to create human embryos specifically for stem cell research. How concerned are you that other countries will gain a competitive advantage over the U.S. if the government does not allow U.S. scientists to do the same? Are you -- very concerned, somewhat concerned, not too concerned or not at all concerned?

Report

The Five Conditions Assessment

Discover a valuable tool for business owners, policymakers and investors to reliably assess companies' potential for growth.

Subscribe to the Gallup News brief and real time alerts.Stay up to date with our latest insights.

Fifty-four percent of Americans think the death penalty is morally acceptable, an all-time low in Gallup's 20-year trend.

While social liberals and social conservatives differ in their views of most moral issues, abortion and gay/lesbian relations are the most divisive.

Americans' perceptions of what is morally acceptable continue to grow more permissive, with their views on several issues the most liberal to date.

Unemployment can be particularly devastating for young adults in high-income countries.

Gallup https://news.gallup.com/poll/21676/Stem-Cell-Research.aspx Gallup World Headquarters, 901 F Street, Washington, D.C., 20001, U.S.A +1 202.715.3030

Here is the original post:
Stem Cell Research | Gallup Historical Trends

For Immediate ReleaseOffice of the Press SecretaryJuly 19, 2006

Fact Sheet: President Bush's Stem Cell Research Policy

President Discusses Stem Cell Research Policy

Today, The President Signed A Bill That Draws A Clear Line Against One Of The Most Egregious Abuses In Biomedical Research And Vetoed A Bill That Attempts To Overturn His Balanced Stem Cell Research Policy:

President Bush Is The First President To Provide Federal Funding For Embryonic Stem Cell Research

In 2001, President Bush Set Forth A New Policy On Stem Cell Research That Struck A Balance Between The Needs Of Science And The Demands Of Conscience. In this new era, our challenge is to harness the power of science to ease human suffering without sanctioning practices that violate the dignity of human life.

Finding New Cures For Disease Does Not Require Destroying Human Embryos

Today, The President Met With Children Who Began Their Lives As Frozen Embryos Created For In Vitro Fertilization. These children were adopted while still embryos, and have been blessed with the chance to grow up in a loving family. They remind us of what is lost when embryos are destroyed in the name of research, that we all began our lives as a small collection of cells, and that America must never abandon our fundamental moral principles in our zeal for new treatments and cures.

Embryonic Stem Cells Come From Human Embryos That Are Destroyed For Their Cells. Each of these human embryos is a unique human life, with inherent dignity and matchless value.

With The Right Techniques And Policies, We Can Achieve Scientific Progress While Living Up To Our Ethical Responsibilities. America was founded on the principle that we are all created equal, and endowed by our Creator with the right to life. We can advance the cause of science while upholding this founding principle.

Since The President Announced His Policy In 2001, Advances In Scientific Research Have Also Shown The Great Potential Of Stem Cells That Are Derived Without Harming Human Embryos. The Administration has expanded the funding of research into stem cells that can be drawn from children, adults, and the blood in umbilical cords, with no harm to the donor - and these stem cells are already being used in medical treatments.

Researchers Are Now Also Investigating New Techniques That Could Allow Doctors And Scientists To Produce Stem Cells Just As Versatile As Those Derived From Human Embryos Without Requiring The Destruction Of These Embryos. One technique scientists are exploring would involve "reprogramming" an adult cell - for example, a skin cell - to function like an embryonic stem cell.

President Bush's Balanced Approach To Stem Cell Research Has Worked

The President's Policy Has Allowed Science To Explore The Potential Of Embryonic Stem Cells - And It Has Allowed America To Continue To Lead The World In This Area. Under the President's policy, 21 human embryonic stem cell lines are currently available for Federal funding, and are in use. Each of these lines can be replicated many times. As a result, the National Institutes of Health have helped make more than 700 shipments to researchers since 2001.

There Is No Ban On Embryonic Stem Cell Research. To the contrary, even critics of the President's policy concede that these Federally funded lines are being used in research every day by scientists across the world.

According To The Most Recent Data, From 1998 To 2004, 85 Percent Of Publications On Human Embryonic Stem Cell Research Involved The Use Of Lines Approved For Funding By NIH. (Jason Owen-Smith and Jennifer McCormick, "An International Gap In Human ES Cell Research," Nature Biotechnology, April 2006)

According To The Most Recent Data, From 1998 To 2004, 46 Percent Of All Human Embryonic Stem Cell Studies Published Have Been Done In American Institutions. (Jason Owen-Smith and Jennifer McCormick, "An International Gap In Human ES Cell Research," Nature Biotechnology, April 2006)

The President Believes We Must Continue To Explore Hopeful Alternatives And Advance The Cause Of Scientific Research While Staying True To The Ideals Of A Decent And Humane Society. At a moment when ethical alternatives are becoming available, we cannot lose the opportunity to conduct research that would give hope to those suffering from terrible diseases and help move our Nation beyond the current controversies over embryonic stem cell research.

# # #

Read this article:
Fact Sheet: President Bush's Stem Cell Research Policy

Express News Service

CHENNAI: Doctors at the Stem Cell Research Centre, Government Stanley Medical College Hospital (GSMCH), are in the process of recruiting patients for conducting phase I and II clinical trials of Stem Cell Therapy for end-stage liver disease to assess its safety and efficacy.

The clinical trial comes as a significant move as presently, liver transplant is the only treatment available for end-stage liver disease, but scarcity of donor organs necessitates alternative modalities. The Stem Cell Research Centre in July 2020 received approval from the Central Drug Standard Control Organisation (CDCSO) to conduct clinical trials after animal trails showed promising results, said Dr S Jeswanth, Director, Institute of Surgical Gastroenterology and Principal Investigator, Stem Cell Research Centre, GSMCH.

Dr Secunda Rupert, Co-Investigator at Stem Cell Research Centre, GSMCH told TNIE that liver transplant is currently the only option for end-stage liver disease. Many patients are on the waiting list for liver transplant. So these stem cells can be used as a bridge till they get donor liver for transplant and in some cases, it can be a wholesome therapy. We have found that in acute liver disease, the results are good, the doctor added.

According to data from the Transplant Authority of Tamil Nadu (TRANSTAN), there are 418 patients waiting for liver transplant in the State alone. The CDSCO gave approval and also directed to conduct more animal studies. We will first conduct them and then will start the clinical trials. We are in the process of recruiting patients for the trial. We couldnt recruit patients then because of the pandemic, said Secunda. A total of 30 patients will be recruited for clinical trials, and among them 15 will be put on Stem Cell Therapy and 15 on standard treatment, added Secunda.

Mesenchymal adult stem cells will be extracted from bone marrow of the patients and these will be cultured in the lab before being injected back into the patient, Secunda added. During animal studies, when we caused liver injury in the animal and injected the stem cells, there was an improvement in the injury. It showed these Mesenchymal adult stem cells can alleviate liver injury, Secunda further said.Jeswanth said the trial will be funded by the Tamil Nadu Innovative Initiative scheme (TANII).

Fast facts

Continued here:
Chennai-based institute to begin clinical trial on stem cell therapy for liver disease - The New Indian Express

A lung transplant can mean the difference between life and death for people with diseases such as pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and even severe COVID-19. Yet, recipients of donor lungs must take daily medications to stave off damage caused by their own immune system, which attacks the organs it recognizes as foreigna process known as rejection.

A new University of Michigan Health study, published in the Journal of Clinical Investigation, has identified cells that appear to play a pivotal role in creating the scarring, or fibrosis, characteristic of chronic rejection following a lung transplant.

Almost 15 years ago, Vibha Lama, MBBS, M.S., a professor in the Division of Pulmonary Disease and Critical Care Medicine, and her lab described the presence of stem-cell-like cells, called mesenchymal stromal cells, in lung sample fluid from lung transplant recipients.

We found that even ten years post-transplant, these cells belonged to the donor, not the recipient, she explained. At that time, we had no clue where in the lung they were coming from or what role they played.

To figure this out, her lab generated a mouse model to recreate what happens within a lung transplant recipient. With the model, they followed a transcription factor known as FOXF1 as a sort of trail of breadcrumbs back to the cells original location.

MORE FROM THE LAB: Subscribe to our weekly newsletter

They discovered that these cells formed a reservoir of stem cells within the bronchovascular bundle deep inside the lung. These bundles contain a bronchus (airway), arteries, connective tissue and other structures and is the part of the lung which connects it to the outside environment.

In this study, explained Lama, who is senior author on the paper, they show that these specific stem cells are interacting with neighboring epithelial cells within that airway niche.

Epithelial cells line and protect the airways and produce a protein known as Sonic hedgehog. Via this protein, epithelial cells signal the stem-cell-like mesenchymal cells, which make up the scaffolding of the lungs, to make FOXF1, a repressor that keeps the stem cells in check.

We are just recently understanding that there are many different kinds of mesenchymal cells in the lung, said Lama. What we describe here is not only are there many kinds of mesenchymal cells, FOXF1 is retained only in these specific stem-cell-like cells.

In the case of lung transplant rejection, Lama hypothesized that immune cells from the recipient attack the epithelial cells which disrupts the balance between them and the mesenchymal cells.

Like Podcasts? Add the Michigan Medicine News Break oniTunes, Google Podcasts or anywhere you listen to podcasts.

Because of the damage caused by rejection, the epithelial cells get damaged, Sonic hedgehog is reduced and that interrupts the signaling to the mesenchymal cells to keep quiet, she said. Because of that, these cells start dividing and they lay down more collagen, which leads to fibrotic scarring.

The work sets the stage for more research into the interaction of these cells with epithelial and other cells it their vicinity to further characterize what happens during chronic rejection and potentially how to prevent it. Furthermore, discovery of these cells is also important in understanding other airway diseases like asthma and COPD.

Paper cited: Transcription factor FOXF1 identifies compartmentally distinct mesenchymal cells with a role in lung allograft fibrogenesis, J Clin Invest. DOI: 10.1172/JCI147343

More:
Stem cells and their role in lung transplant rejection - Michigan Medicine

It is too late for conservation efforts to save the northern white rhinoceros, but with recent scientific advancements there may still be hope to bring back this beloved species. In a recently published paper, scientist Marisa Korody and her colleagues at San Diego Zoo Global (USA) and at the Department of Molecular Medicine at Scripps Research (USA) describe their exciting progress on using stem cells to revive the northern white rhino.

The northern white rhino is functionally extinct, meaning there are not enough of these rhinos left to save the species. In fact there are only two northern white rhinos left: a mother and a daughter. But for decades, scientists have preserved cell samples from 15 northern white rhinos containing enough genetic material to potentially bring this species back from the brink. These preserved samples hold fibroblast cells the type of skin cells that secrete collagen from white rhinos. With these scientists newly developed methods, fibroblast cells can be converted into something much more valuable: induced pluripotent stem cells. These stem cells can differentiate into any cell type in the body including heart cells, muscle cells, and reproductive cells.

In theory, by converting fibroblast cells into reproductive cells, scientists could create genetically unique rhino embryos. Alongside other assisted reproduction technologies, scientists could implant a new embryo into a closely-related southern white rhino, where the baby northern white rhino could develop as an otherwise normal pregnancy. By completing this process multiple times, scientists may be able to establish a stable population of northern white rhinos.

In 2011, this research team generated induced pluripotent stem cells from the samples of another endangered species, but unfortunately since this process was found to harm the recipient genomes, this method was largely unsuccessful. Despite this setback, in 2015 the authors met with colleagues worldwide to consider ways to save the northern white rhino, and they concluded that methods involving induced pluripotent stem cells may still be the most promising solution. Over the following years, the scientists worked to improve their methods, and these improvements are documented in their recent paper. These experiments represent the first step in a long-term plan to bring the northern white rhino back through assisted reproduction techniques.

Right from the start, the scientists faced a whole host of challenges. Through trial and error they modified the growth medium for the cells, optimizing it for rhinoceros cells. With their improved growth medium, scientists successfully generated induced pluripotent stem cell lines from 11 rhinoceros individuals. This has never been done before and represents a huge stride forward in the path to recovering this species.

Before trying to make their first rhino, the scientists needed to stress these induced pluripotent stem cells and sequence their genomes to determine if the cell quality is good enough to potentially produce new, viable rhinos. They maintained colonies of these cells in long-term cultures and exposed these colonies to different conditions to give insight into how resilient these cells could be. These tests demonstrated that long-term culture did not affect the potential for these cells to differentiate into cardiac lineage cells, confirming that these cells are stable long-term. The researchers also confirmed that these pluripotent cells could potentially produce gametes, the egg and sperm cells that are used for sexual reproduction. These advancements indicate that with these newly developed protocols, induced pluripotent stem cells are a promising tool that could someday help recover the northern white rhino.

Although this study includes some exciting results, there is still much work to do. For example, scientists must now sequence the genomes of the northern and southern white rhino so other researchers can analyze the stem cells ability to stay the same over time. Despite the work that still needs to be done, these promising advancements could someday help the northern white rhino population recover. This method may also work for saving other endangered or extinct species, as long as the genetic material needed is available. Long-term, these scientists plan to continue a series of experiments that could ultimately bring this beloved rhino, and potentially other endangered species, back from the brink of extinction.

Excerpt from:
Stem cells may be the key to saving white rhinos from extinction - Sciworthy

Published: Oct. 4, 2021 at 2:02 PM MDT

ORLANDO, Fla., Oct. 4, 2021 /PRNewswire/ --Billions of dollars are spent every year because of complications of wound healing. Researchers at the College of Medicine at the University of Central Florida (UCF) in Orlando have discovered a new technology to accelerate wound healing. Their research is published in the Life Cell Biology and Tissue Engineering Journal (https://pubmed.ncbi.nlm.nih.gov/34575027/). The UCF lab's research focus is to develop stem cell therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, wound healing and ALS.

Researchers at the College of Medicine at UCF in Orlando have discovered a new technology to accelerate wound healing.

Dr. Frederick R Carrick, Professor of Neurology at the College of Medicine at UCF, reported that animals with wounds and injured stem cells that were placed on a special ceramic blanket healed much faster than controls. Gladiator Therapeutics manufactured the therapeutic ceramic blanket that was used in this research. The researchers reported that wounds in animals and in stem cells were both repaired significantly faster when they treated them with the ceramic blankets.

This research was designed and accepted for presentation at the USA Department of Defense's premier scientific meeting, the Military Health System Research Symposium (MHSRS). Dr Carrick stated that the new ceramic blankets do not need a power supply and are ideally suited for use in both combat and civilian wound treatments. Large wounds, such as those suffered in combat are easily infected and may result in increased suffering, disability and death amongst Warfighters. Faster healing of wounds can decrease pain and suffering and save lives.

The UCF College of Medicine research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's and Parkinson's disease, traumatic brain injury and wound care. They have recently developed a new Alzheimer's therapy combining drugs that affect stem cells that increase the development of brain cells and improve brain function. The UCF lab is also the first to transplant stem cells isolated from the human brain to aged rats where they showed increased development of new brain cells and improvement of cognition.

Dr. Kiminobu Sugaya, Professor of Medicine at the UCF College of Medicine is excited about their findings. Dr. Sugaya stated that the benefits of using the Gladiator ceramic blanket are that it can be used anywhere without a power supply or the side effects that are commonly found when injecting chemicals or drugs.

Further information about this study:

drfrcarrick@post.harvard.edu 321-868-6464

View original content to download multimedia:

SOURCE University of Central Florida College of Medicine

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Read more from the original source:
Faster healing of wounds can decrease pain and suffering and save lives - KKTV 11 News

Cell therapy plays an important role in vascular and hematopoietic, neural, skeletal, pancreatic, periodontal, and mucosal tissue regeneration. Platelet-derived growth factors and bone morphogenetic factors are gaining high demand for diabetic neuropathic ulcers and periodontal defects, and tissue regeneration at sites of tibia fractures. Increasing demand for transforming growth factors in regenerative medicine is expected to propel market growth substantially over the coming years.

Stem cell research continues to expand due to high adoption of stem cell treatment. Therefore, bone morphogenetic proteins (BMPs) and TGF-beta proteins are gaining demand and supporting the clinical development of cellular therapies. Cell culture has helped the most in oncology research as cancer cells are more responsive to culture in vitro, which, in turn, is drive demand in research areas.

Increasing healthcare R&D expenditure further improves the chances of breakthrough treatment options. Rapidly growing healthcare expenditure is resulting in new molecule discovery, evaluation of various molecules for possible disease treatment, and adoption of innovative approaches in these studies.

Request for sample PDF of report: https://www.persistencemarketresearch.com/samples/32813

Key manufacturers of transforming growth factor are focusing on the development of technology to cater to specific research requirements.

The COVID-19 pandemic affected health services for other diseases such as hypertension, cancer, diabetes, and cardiovascular diseases. Selective procedures such as orthopedic joint replacement were impacted. Shifted focus of healthcare professionals from these diseases to address the COVID-19 crisis negatively impacted the overall healthcare industry.

However, the transforming growth factor space did not see any long-term adverse effect on its business. A short-term impact of COVID-19 has been seen on the market due to disruptions in the supply chain and research activities during lockdowns. The market is projected to experience smooth growth over the coming years.

Get customized report by asking an expert: https://www.persistencemarketresearch.com/ask-an-expert/32813

Key Takeaways from Market Stud

By grade, the GMP segment is fast-growing at CAGR of 9.3%, on the back of rise is demand for supreme quality growth factors across regions.

Based on product, bone morphogenetic proteins (BMPs) is leading with over 43% market share.

Oncology research is estimated to lead the market by application. This segment accounted for approximately 22% share of the market.

Pharmaceutical and biotechnology companies lead demand for transforming growth factors with a market share of 48%.

By region, North America is set dominate the global market with a value share of around 41%. Europe is slated to be the second-largest leading region with a value share of 32%.

"Increasing drug discovery and stem cell research is expected to drive market expansion of transforming growth factors over the next ten years," says an analyst of Persistence Market Research.

Get full access of report: https://www.persistencemarketresearch.com/checkout/32813

Market Competition

Agreements, collaborations, and partnerships have emerged as the key growth strategy adopted by industry players. By focusing on these strategies, key stakeholders are expanding their geographic footprints and strengthening their existing product portfolios.

In February, 2019, Roche entered into a definitive merger agreement to acquire Spark Therapeutics.

In 2021, Bio-Techne Corporation) and Catamaran Bio expanded their collaboration for the development of cell engineering and cell process technologies for use by Catamaran in the manufacturing of CAR-NK cell therapy products.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the transforming growth factor market in its latest study, presenting historical demand assessment of 2016 2020 and projections for 2021 2031.

The research study is based on the product (activin, bone morphogenetic proteins (BMPs), TGF-beta proteins), grade (GMP grade, NON-GMP grade), application (oncology research, haematology research, wound healing research, dermatology research, cardiovascular disease & diabetes, cell therapy and ex vivo manufacturing, others), end user (pharmaceutical and biotechnology companies, research centres & academic institutes, CMOs and CDMOs), across seven key regions of the world.

Related Reports:

About Persistence Market Research:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Overview:

Persistence Market Research is always way ahead of its time. In other words, it tables market solutions by stepping into the companies'/clients' shoes much before they themselves have a sneak pick into the market. The pro-active approach followed by experts at Persistence Market Research helps companies/clients lay their hands on techno-commercial insights beforehand, so that the subsequent course of action could be simplified on their part.

Contact

Rajendra Singh Persistence Market Research U.S. Sales Office:305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [emailprotected]Visit Our Website:https://www.persistencemarketresearch.com

SOURCE Persistence Market Research Pvt. Ltd.

See the article here:
Transforming Growth Factor Sales Gaining Traction & to reach US$ 709.9 Mn with Significant Development in Cell Therapy Research - PRNewswire